Fat Loss + GH Synergy Stack
A powerful metabolic stack combining Retatrutide — a triple-agonist incretin (GLP-1/GIP/glucagon) — with Tesamorelin, a growth-hormone-releasing hormone (GHRH) analog. Retatrutide drives aggressive fat loss. Tesamorelin adds GH-mediated recovery, muscle preservation via IGF-1 upregulation, and targeted visceral fat reduction.
Retatrutide is the fat loss engine — triple-receptor agonism produces more potent appetite suppression and metabolic activation than single or dual agonists. Tesamorelin adds a GH/recovery axis that preserves lean mass, supports sleep quality, and independently targets visceral adipose tissue. Together they create a fat loss protocol that protects muscle and accelerates body composition changes.
| Parameter | Details |
|---|---|
| Starting Dose | 1–2 mg/week |
| Titration Target | Up to 10–12 mg/week |
| Preferred Administration | Daily injections (divide weekly dose) |
| Route | Subcutaneous injection |
| Cycle Length | 8–16 weeks |
| Parameter | Details |
|---|---|
| Dose Range | 1–2 mg daily |
| Ceiling Dose | 2 mg daily |
| Timing | Before bed |
| Route | Subcutaneous injection |
| Frequency | Daily |
| Parameter | Details |
|---|---|
| Retatrutide Cycle | 8–16 weeks |
| Tesamorelin | Nightly throughout the cycle |
| Titration | Start Retatrutide low and titrate up over 2–4 weeks to manage GI side effects |
Clinical Note
Track fasting glucose, HbA1c, lipid panel, IGF-1, and liver enzymes at baseline and every 4–6 weeks. Prescriber authorization required for dose adjustments.
This guide is for educational and clinical-support purposes only. All dosing must be supervised by a licensed prescriber. Matrix Advanced Solutions does not provide medical advice. Always consult your healthcare provider before starting any peptide protocol.